GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » 3-Year Revenue Growth Rate

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) 3-Year Revenue Growth Rate : 27.20% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi 3-Year Revenue Growth Rate?

Laboratorios Farmaceuticos Rovi's Revenue per Share for the three months ended in Dec. 2023 was €4.53.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Revenue per Share Growth Rate was 2.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 27.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 24.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Laboratorios Farmaceuticos Rovi was 30.30% per year. The lowest was 5.30% per year. And the median was 11.00% per year.


Competitive Comparison of Laboratorios Farmaceuticos Rovi's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year Revenue Growth Rate falls into.



Laboratorios Farmaceuticos Rovi 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Laboratorios Farmaceuticos Rovi 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

George Soros Buys Rovi Corp

By Kyle Ferguson Kyle Ferguson 09-08-2016

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 529,463 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 96,461 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 10,833 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 44,145 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

ITC Reaffirms TiVo's Second Infringement Victory

By Business Wire Business Wire 04-23-2020